

INNOVA CAPTAB LIMITED  
Plot No. 320, Industrial Area, Phase-1,  
Panchkula, Pin-134113, Haryana, India.  
Phone: +91-172-4194500



**07<sup>th</sup> May, 2026**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**BSE Symbol: INNOVACAP**  
**BSE Scrip Code: 544067**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400051  
**NSE Symbol: INNOVACAP**

Dear Sir/Madam,

**Subject: Press Release**

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release issued by the Company on the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31<sup>st</sup> March, 2026.

The Press Release will also be available on the website of the Company at <https://www.innovacaptab.com>.

This is for your information and record.

Thanking you,

Yours faithfully,  
**For Innova Captab Limited**

**Neeharika Shukla**  
**Company Secretary and Compliance Officer**

***Encl.: As above***

## INNOVA CAPTAB LIMITED

### Press Release

#### Innova Captab Limited reported healthy results for Q4 FY26, with Revenue from Operations at ₹ 447.8 crores and EBITDA at ₹ 66.7 crores

**Mumbai, 7<sup>th</sup> May, 2026:** Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its audited financial results for the quarter and year ended March 31st, 2026.

#### Financial Summary:

Particulars (₹ Crs.)	Q4FY26	Q4FY25	YoY (%)	FY26	FY25	YoY (%)
Revenue from operations	447.8	314.7	42.3%	1,630.0	1,243.7	31.1%
EBITDA	66.7	51.1	30.5%	250.3	198.2	26.3%
<i>EBITDA Margin</i>	<i>14.9%</i>	<i>16.2%</i>	<i>(130 bps)</i>	<i>15.4%</i>	<i>15.9%</i>	<i>(50 bps)</i>
PAT	38.1	29.6	28.8%	140.9	128.3	9.9%

#### Q4FY26 vs. Q4 FY25 Performance:

- Revenue from Operations registered strong growth of 42.3% to ₹ 447.8 crores vs. ₹ 314.7 crores
- Recorded EBITDA growth of 30.5% to ₹ 66.7 crores vs. ₹ 51.1 crores. EBITDA margin for the quarter was 14.9%
- PAT for the quarter was ₹ 38.1 crores, registering growth of 28.8%. PAT margin was 8.5%

#### FY26 vs. FY25 Performance:

- Revenue from Operations for FY26 cumulated to ₹ 1,630.0 crores vs. ₹ 1,243.7 crores in FY25 clocking growth of 31.1%
- EBITDA for FY26 stood at ₹ 250.3 crores vs. ₹ 198.2 crores in FY25, growing at 26.3%. EBITDA margin was 15.4%
- Profit after Tax was ₹ 140.9 crores. PAT margin came in at 8.6%

**Commenting on the company's performance, Mr. Vinay Lohariwala, Managing Director, Innova Captab Limited,** said "Innova Captab Ltd has a strong performance with YoY revenue growth of 42% in Q4 FY26 and has delivered its highest-ever annual revenue with a growth of 31% in FY26. This strong performance underscores disciplined execution across our operations.

This milestone performance was driven by sustained momentum across our CDMO and branded generics businesses, supported by an expanding product portfolio and increasing customer engagement.

Operational excellence remains central, backed by state-of-the-art manufacturing infrastructure and stringent quality processes. During the year, we received key certifications including UK-MHRA for our Baddi facility and PIC/S for our Jammu blocks, enhancing our presence in regulated markets.

The Jammu facility has completed its first full year of operations and is ramping up well, with multiple marquee clients successfully completing regulatory and customer audits.

With multiple growth levers in place, we remain confident in sustaining momentum and delivering long-term value to our stakeholders.”

**About Innova Captab Limited**

*Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company in India with a comprehensive business model and presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides an elaborate suit of pharmaceutical products to over 350 clients in India and key international markets. Apart from this, the company has strong direct presence across India and international markets with its Branded Generics Business. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA, PIC/s among others. For more details, please visit [www.innovacaptab.com](http://www.innovacaptab.com)*

**For more information, please contact:**

<b><u>Company Details</u></b>	<b><u>Investor Relations Advisors</u></b>
<p><b><u>Innova Captab Ltd.</u></b></p>  <p>CIN: L24246MH2005PLC150371  <b>Mr. Lokesh Bhasin</b>  <b>Email Id – <a href="mailto:investors@innovacaptab.com">investors@innovacaptab.com</a></b>  <a href="http://www.innovacaptab.com">www.innovacaptab.com</a></p>	<p><b><u>Strategic Growth Advisors Pvt. Ltd.</u></b></p>  <p>CIN - U74140MH2010PTC204285  Ms. Shaily Patwa/ Mr. Shrikant Sangani  Email - <a href="mailto:shaily.p@sgapl.net">shaily.p@sgapl.net</a> / <a href="mailto:shrikant.sangani@sgapl.net">shrikant.sangani@sgapl.net</a>  Mobile No – 9819494608 / 9619595686  <a href="http://www.sgapl.net">www.sgapl.net</a></p>

**DISCLAIMER:**

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.